Omeros Corporation
Omeros Corporation logo
OMER

Omeros Corporation (OMER)

$2.040.49%

Market is closed
– opens on 8 PM, 07 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$2.0399
Day's Range
$2.105
$1.86
52-Week Range
$8.33
1 month return37.8%
3 month return62.71%
1 year return73.16%
5 year return89.88%

Company Information

Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its commercial product OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% continues to gain market share in cataract surgery. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under priority review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19. OMS906, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in a Phase 1 clinical trial, and the company's PDE7 inhibitor program OMS527, targeting addiction and movement disorders, has successfully completed a Phase 1 trial. Omeros' pipeline holds a diverse group of preclinical programs including a proprietary-asset-enabled antibody-generating technology and a proprietary GPCR platform through which it controls 54 GPCR drug targets and their corresponding compounds. One of these novel targets, GPR174, modulates a new cancer immunity axis recently discovered by Omeros, and the company is advancing GPR174-targeting antibodies and small-molecule inhibitors.
OrganizationOmeros Corporation
Employees213
CEODr. Gregory A. Demopulos M.D.
IndustryHealth Technology

Analyst Recommendation

based on 7 analysts ratings

Buy
57%
Buy
28%
Hold
14%
Sell

Based on 7 Wall street analysts offering stock ratings for Omeros Corporation(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 815.2%

Current

$2.04

Target

$18.67

Recommendation Trend

Based on 7 analyst

Current1M Ago3M Ago
Buy
4
8
7
Hold
2
4
3
Sell
1
1
1
Consensus
BUY
BUY
BUY

Highlights

Market Capitalization
127.3M
Book Value
$0.38
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
3.14
PE Ratio
0.65
PEG Ratio
-0.17
Wall Street Target Price
18.67

Valuation

Trailing PE0.65
Forward PE0.0
Price/Book (mrq)
8.44
Enterprise Value
250.4M
Enterprise Value/Revenue
8.26
Enterprise Value/Ebitda
-1.54

Technicals

Beta
1.1
50 Day MA
3.06
200 Day MA
4.16

Institutional Holdings

Ingalls & Snyder LLC

6.52%

Vanguard Group Inc

4.49%

D. E. Shaw & Co LP

3.2%

Stifel Financial Corp

2.08%

Millennium Management LLC

1.95%

BlackRock Inc

1.82%

Discover more

Frequently Asked Questions

What is Omeros Corporation share price today?

Can Indians buy Omeros Corporation shares?

How can I buy Omeros Corporation shares from India?

Can Fractional shares of Omeros Corporation be purchased?

What are the documents required to start investing in Omeros Corporation stocks?

What are today’s High and Low prices of Omeros Corporation?

What are today’s traded volumes of Omeros Corporation?

What is today’s market capitalisation of Omeros Corporation?

What is the 52 Week High and Low Range of Omeros Corporation?

How much percentage Omeros Corporation is down from its 52 Week High?

How much percentage Omeros Corporation is up from its 52 Week low?

What are the historical returns of Omeros Corporation?

Who is the Chief Executive Officer (CEO) of Omeros Corporation?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*